REPRESENTATIVE CASES

In re Alphabet, Inc. Shareholder Litig.
No. 3:21-cv-09388-RFL
Shareholder derivative action arising from Alphabet Inc.’s alleged violations of U.S. antitrust law in connection with the company’s search, Ad Tech, and Android mobile operating system and app distribution businesses; $500 million settlement to fund the overhaul of the Alphabet’s global corporate compliance program

In re Facebook, Inc. Stockholder Litig.
C.A. No. 2018-0307-KSJM
Shareholder derivative action arising from Facebook, Inc.’s alleged violations of user privacy standards and the Cambridge Analytica scandal, as well as alleged insider trading by Mark Zuckerberg; mid-trial settlement (subject to court approval) consisting of $190 million cash recovery and corporate governance reforms in the first ever Caremark case to proceed to trial

Irving Firemen’s Relief and Retirement Fund v. Page (Alphabet, Inc.)
C.A. No. 2019-0355-SG (Del. Ch.)
Shareholder derivative action concerning the Alphabet Board of Directors alleged “pattern of concealment” sexual misconduct and failure to protect customer data, all at the expense of shareholders; $310 million settlement on behalf to fund Company-wide workplace diversity and equity initiatives, as well as enhanced sexual harassment protections and data breach protections

In re Altria Group, Inc. Derivative Litig.
No. 3:20-cv-00772 (DJN) (E.D. Va.)
Shareholder derivative action concerning Altria Group’s investment in Juul Labs, Inc., which engaged in the sale and marketing of vaping products; $117 million settlement to fund anti-youth vaping programs, as well as enhanced transactional oversight

Rudi v. Wexner (L Brands / Victoria’s Secret)
No. 2:20-cv-03068 (S.D. Ohio)
Shareholder derivative action concerning the L Brands Board of Directors’ alleged failures in allowing a culture of sexual harassment to plague the company; $90 million settlement to fund diversity, equity and inclusion initiatives, increased training and oversight of contractors, revamping of sexual harassment and anti-retaliation policies, and elimination or non-enforcement of non-disclosure agreements

In re Abbott Laboratories Infant Formula S’holder Derivative Litig.
No. 1:22-cv-5513 (N.D. Ill.)
Shareholder derivative action arising from alleged bad faith conduct and false statements by directors and officers of Abbott Laboratories in connection with Abbott’s U.S. infant formula business, its nationwide product recall, and various related enforcement actions by the DOJ and FDA.

 In re The Boeing Co. Derivative Litig.
C.A. No. 2024-1210-MTZ (Del. Ch.) & No. 1:24-cv-1200 (E.D. Va.)
Shareholder derivative actions alleging bad faith conduct and false statements by directors and officers of The Boeing Company related to airplane safety and compliance violations

In re Illumina, Inc. Consol. Derivative S’holder Litig.
C.A. No. 2024-1337-PAF
Shareholder derivative action arising from Illumina, Inc.’s $8 billion acquisition of healthcare company GRAIL and alleged violations of regulatory standstill obligations